Characteristics of included studies (2,911 participating GPs).

Detailed clinical, electrodiagnostic and sonographic findings of all patients. (AD—active denervation, APD—anterior-posterior diameter, BR—brachioradialis muscle, ECR—extensor...

Patent information of marketed HBV drugsa.

Correlation between visual acuity after treatment and demographic, clinical, electrophysical and MRI parameters.

Comparison of variation of cost, life expectancy and quality-adjusted lifeyears.

Quality of evidence supporting psychological treatment of depressive symptoms in people aged 65 years and over.

Fulfillment (%) of SPIN items in result and conclusion sections.

BackgroundThere are no therapies shown to improve outcome after severe traumatic brain injury (TBI) in humans, a leading cause of morbidity and mortality. We sought to verify...

Tumor molecular profiling plays an integral role in identifying genomic anomalies which may help in personalizing cancer treatments, improving patient outcomes and minimizing...

Results of sensitivity analyses which altered cost-effective intervention.

a Liu et al., 2011 [19]. b Ji et al., 2007 [20]. c Wei et al., 2010 [21]. d Noteborn et al., 2013 [22]. *Positions correspond to: IBDV (JQ684022), IBV (KJ425500), AEV...

ELISA results (mean levels) of 6 factors with significant difference of expression in protein array.

Baseline characteristics of the older residents of geriatric health service facilities.

Barriers (b) and facilitators (f) for physiotherapists to advise patients with neck pain to visit the manual therapist.

Studies evaluating treatment patterns in patients with advanced non-small cell lung cancer by country.

IntroductionThe need for specialized care, particularly enteral nutritional therapy in community settings is now increasing with implications for both patients and primary care...

Quality assessment of the included trials.

Participant characteristics interviews (n = 57).

Complication rates in ICH patients with and without follow-up data.

Abbreviation: 5ARI, 5-alpha reductase inhibitor. Demographic characteristics of the study cohort and controls (n = 11,481).